Holen Sie sich die Stockscreener-App
27.05
0.59%
-0.16
Handel nachbörslich:
27.05
Schlusskurs vom Vortag:
$27.21
Offen:
$27.18
24-Stunden-Volumen:
144.29K
Relative Volume:
0.52
Marktkapitalisierung:
$918.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-21.21%
1M Leistung:
-7.24%
6M Leistung:
+34.58%
1J Leistung:
+0.00%
1-Tages-Spanne:
$26.40
$27.61
1-Wochen-Bereich:
$26.40
$34.35
52-Wochen-Spanne:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AVBP | 27.05 | 918.24M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Receives Buy Rating from HC Wainwright - MarketBeat
ArriVent BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ArriVent BioPharma Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
ArriVent Reports $282.9M Cash Position, Firmonertinib Shows Promise in NSCLC Trial | AVBP Stock News - StockTitan
FMR LLC's Strategic Acquisition of ArriVent BioPharma Inc Shares - GuruFocus.com
(AVBP) On The My Stocks Page - Stock Traders Daily
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MSN
AlphaCentric Advisors LLC Cuts Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
Long Term Trading Analysis for (AVBP) - Stock Traders Daily
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MSN
ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month HighShould You Buy? - MarketBeat
ArriVent To Present FURTHER Data At The 2024 World Conference On Lung Cancer - RTTNews
When the Price of (AVBP) Talks, People Listen - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 80.1% in September - MarketBeat
Octagon Capital Advisors LP Increases Stake in ArriVent BioPharma Inc - Yahoo Finance
(AVBP) Proactive Strategies - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Shares Up 6.3% - MarketBeat
Novo Holdings A S Buys 422,860 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.4% in September - MarketBeat
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Rises By 13.4% - MarketBeat
Regeneron purchases former Quad Graphics site in Saratoga Springs - MSN
How to Take Advantage of moves in (AVBP) - Stock Traders Daily
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Simply Wall St
Bank of New York Mellon Corp Grows Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6% - MarketBeat
It makes sense and dollars to buy ArriVent BioPharma Inc. (AVBP) stock - SETE News
ArriVent BioPharma, Inc.(NasdaqGM:AVBP) added to S&P Biotechnology Select Industry Index - Marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $23.94 - Defense World
Was ArriVent BioPharma Inc. (AVBP)’s session last reading good? - US Post News
Closing Figures: ArriVent BioPharma Inc. (AVBP)’s Positive Finish at 24.20, Up 2.59 - The Dwinnex
ArriVent BioPharma: Bringing A Novel Cancer Drug From China (NASDAQ:AVBP) - Seeking Alpha
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $36.00 by Analysts at Citigroup - Defense World
Citigroup Raises ArriVent BioPharma (NASDAQ:AVBP) Price Target to $36.00 - MarketBeat
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer - Scrip
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% - MarketBeat
Global economic uncertainty takes toll on China’s biotech ecosystem - BioWorld Online
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Given Outperform Rating at Oppenheimer - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $38.00 by Analysts at The Goldman Sachs Group - Defense World
ArriVent BioPharma shares see boost as Citi ups price target By Investing.com - Investing.com Canada
ArriVent BioPharma stock target raised on positive trial results By Investing.com - Investing.com Canada
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Should investors be concerned about ArriVent BioPharma Inc. (AVBP)? - US Post News
Analyst boosts ArriVent BioPharma shares price target after promising trial data - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - MarketBeat
ArriVent reports promising data on lung cancer drug firmonertinib - Investing.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - ForexTV.com
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Es liegen keine Finanzdaten für Arrivent Biopharma Inc (AVBP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):